Pharmacokinetics of tebipenem pivoxil used in children suffering from shigellosis: a pilot study in Bangladesh
2024

Study on Tebipenem for Treating Shigellosis in Children

Sample size: 30 publication Evidence: moderate

Author Information

Author(s): Nuzhat Sharika, Islam Md Ridwan, Bashar Syed Jayedul, Das Subhasish, Amin Rukaeya, Qadri Firdausi, Khanam Farhana, Ahmed Dilruba, Pavlinac Patricia B., Zhang Cindy X., Arnold Samuel L. M., Newlands Amy, Chisti Mohammod Jobayer, Ahmed Tahmeed

Primary Institution: International Centre for Diarrhoeal Disease Research, Bangladesh (icddr,b)

Hypothesis

Can tebipenem pivoxil be safely used to treat childhood shigellosis?

Conclusion

Tebipenem pivoxil is as effective and safe as azithromycin for treating childhood shigellosis.

Supporting Evidence

  • Clinical success was observed in 7 participants in each treatment arm.
  • Tebipenem showed comparable pharmacokinetics to azithromycin.
  • Both treatments had similar tolerability with no significant adverse events.

Takeaway

This study tested a new medicine called tebipenem to see if it works for kids with a tummy bug called shigellosis, and it seems to work just as well as an older medicine.

Methodology

A randomized pilot clinical trial comparing tebipenem pivoxil and azithromycin in children with shigellosis.

Limitations

The small sample size limits the ability to generalize the findings.

Participant Demographics

Children aged 24-59 months with suspected shigellosis.

Digital Object Identifier (DOI)

10.1038/s41598-024-83549-3

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication